Enhanced stromal syndecan-1 expression is an independent risk factor for poor survival in bladder cancer.
about
Prognostic and clinical significance of syndecan-1 in colorectal cancer: a meta-analysisSyndecan-1 in Cancer: Implications for Cell Signaling, Differentiation, and PrognosticationMolecular and clinical profiles of syndecan-1 in solid and hematological cancer for prognosis and precision medicineMechanisms of heparanase inhibitors in cancer therapy.The interplay of extracellular matrix and microbiome in urothelial bladder cancer.The Role of Heparanase and Sulfatases in the Modification of Heparan Sulfate Proteoglycans within the Tumor Microenvironment and Opportunities for Novel Cancer Therapeutics.Key signaling pathways in the muscle-invasive bladder carcinoma: Clinical markers for disease modeling and optimized treatment.Shed proteoglycans in tumor stroma.Endothelial Glycocalyx as Biomarker for Cardiovascular Diseases: Mechanistic and Clinical Implications.Over forty years of bladder cancer glycobiology: Where do glycans stand facing precision oncology?Prognostic value of baseline seric Syndecan-1 in initially unresectable metastatic colorectal cancer patients: a simple biological score.Clinicopathological and prognostic significance of SDC1 overexpression in breast cancer.[Tumour-stroma interactions in urothelial cancer].Exploration of genetics commonness between bladder cancer and breast cancer based on a silcio analysis on disease subtypes.Cancer Cell Glycocalyx and Its Significance in Cancer Progression
P2860
Q26777707-3240BD89-CEA7-4CF3-ACF3-0B000039EACBQ26784262-CF3FAE25-B8FF-4D10-9AF1-8B5D45964DE1Q26796247-7AE38486-E8A3-4F91-8146-BA1CAAB9F619Q30244089-661D57E0-75D8-46B8-98EC-EEBEB3330DF8Q35868405-6A2EAD7D-04B6-47A6-89BD-FB0298F3D83DQ38238094-0C361D5F-F015-4EF3-93E8-2C4339465D03Q38627721-7A877D51-D94B-42E6-AC18-D30A88B99484Q38882752-E690C292-492E-4A65-A7D5-2C3B4EE04968Q39148919-CB0926DB-477E-4CAF-BC18-B45E194FF0FDQ47281580-CF936412-6115-4594-B339-560B6B391FA1Q48136626-AEE53414-3B4D-4C73-ABFE-2AED0C48CBC8Q49689467-1FBBF4F8-0CA8-42DD-8784-787E1AC1DBF6Q53536050-51444447-5401-4A02-A63E-079A8F140042Q55423400-10A3F773-0FEB-4C40-9C11-2632E228D7B0Q57168005-29052DDF-C9A3-46A3-8B51-94557570A51A
P2860
Enhanced stromal syndecan-1 expression is an independent risk factor for poor survival in bladder cancer.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Enhanced stromal syndecan-1 ex ...... or survival in bladder cancer.
@en
Enhanced stromal syndecan-1 ex ...... or survival in bladder cancer.
@nl
type
label
Enhanced stromal syndecan-1 ex ...... or survival in bladder cancer.
@en
Enhanced stromal syndecan-1 ex ...... or survival in bladder cancer.
@nl
prefLabel
Enhanced stromal syndecan-1 ex ...... or survival in bladder cancer.
@en
Enhanced stromal syndecan-1 ex ...... or survival in bladder cancer.
@nl
P2093
P1433
P1476
Enhanced stromal syndecan-1 ex ...... or survival in bladder cancer.
@en
P2093
Frank Vom Dorp
Gero Kramer
Herbert Rübben
Ilona Kovalszky
Kurt W Schmid
Shahrokh F Shariat
Stephan Tschirdewahn
Tibor Szarvas
P304
P356
10.1016/J.HUMPATH.2013.10.036
P407
P50
P577
2013-12-18T00:00:00Z